A Claritas Rx case study showcases the transformative power of the company’s Ascend® Platform in supporting patient access, faster actions, and quantifiable financial impact for specialty therapies. A mid-sized U.S. pharmaceutical brand relied on the platform to boost patient conversions and adherence for an oral oncology drug, targeting longstanding challenges with delayed processing and refill interruptions.
Tackling Critical Challenges
The company aimed to overcome:
- Low first fill rates for patients who waited over 21 days to make a therapy decision.
- Reduced refill rates for patients experiencing more than 41 days of out-of-stock delays.
- The need for seamless, coordinated action among multiple channel partners, ensuring patients could start and stay on therapy at the right time.
Measurable Results and Financial Impact
By deploying the Claritas Rx Ascend Platform, the client’s team:
- Averaged 4,500 intervention actions quarterly, driving rapid response times from channel partners—typically under one day.
- Increased first fill rates by 11-13% among patients with longer decision times.
- Improved refill rates by 13%-25% for cohorts facing out-of-stock periods longer than 41 days.
- Generated a remarkable 2,211 incremental patient-months on therapy (1,993 for new fills and 218 for refills).
- Realized a total financial value exceeding $30 million as a direct result of these additional patient-months on therapy.
The Power of Coordinated Interventions
This case study highlights the effectiveness of coordinated, data-driven actions to resolve access barriers in specialty pharmaceutical patient support. By accelerating patient intervention and improving fill rates, the Ascend Platform not only improved patient outcomes and therapy continuity, but also delivered tangible financial value for the client.
For specialty pharmaceutical programs seeking to maximize patient retention, financial outcomes, and therapy impact, Claritas Rx’s Ascend Platform represents a proven, results-driven solution.
Source: Claritas Rx, data on file, August 2025. Case study based on a mid-sized pharmaceutical company’s oral oncology drug.